Santé Ventures, an Austin, Texas- and Boston, MA-based early-stage healthcare and life sciences investment firm, closed its Fund IV, at $260m.
Fund IV secured capital commitments from more than two-dozen limited partners, including the Pennsylvania Public School Employees’ Retirement System (“PSERS”) and new institutional investors in Asia and Latin America. Returning limited partners in previous Santé funds accounted for nearly 90% of the total capital.
The new vehcile fund will make strategic investments across early-stage Biotech, Healthtech, and Medtech companies.
The fund will build a portfolio of 15-25 investments in innovative companies with the potential to deliver better health outcomes at lower cost. The firm typically leads or co-leads Seed or Series A fundraising rounds.
Founded in 2006, Santé Ventures is a specialized healthcare and life sciences investment firm with nearly $1BN in capital under management. Recent successes include Farapulse (Boston Scientific), Claret Medical (Boston Scientific), TVA Medical (Becton Dickinson), Millipede Medical (Boston Scientific), Molecular Templates (MTEM), AbVitro (Celgene), and Explorys (IBM Corp).
FinSMEs
16/09/2021